Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only.All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

AntiObesity_6MG

AOD-9604

AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH), corresponding to amino acids 177–191. This modified peptide was designed to isolate specific biological signaling properties of hGH while excluding regions associated with growth-promoting activity. Due to its defined structure and reproducible synthesis, AOD-9604 is utilized as a research reagent in laboratory studies examining metabolic signaling pathways, peptide–receptor interactions, and structure–function relationships related to growth hormone fragments.*

  • Peptide Identity: AOD-9604 (hGH fragment 177–191, modified)
  • Peptide Class: Synthetic peptide fragment
  • Form: Lyophilized powder
  • Purity: ≥99% (HPLC verified)
  • Quantity: 6 mg per vial
  • Analytical Verification: HPLC and Mass Spectrometry (MS)
  • Manufacturing: Synthesized and quality-tested under controlled laboratory conditions
  • Designation: For Research Use Only (RUO)

$75.00

$71.25 each
$67.50 each

Products will arrive in a lyophilized (powder) form for maximum stability.

Free domestic shipping on orders over $300

AOD-9604

Scientific & Research Context

AOD-9604 has been investigated in preclinical and in vitro research as a biologically active fragment of human growth hormone.* Published studies have examined its interaction with metabolic and lipolytic signaling pathways, with a focus on isolating specific functional domains of hGH while minimizing broader systemic activity associated with the full-length hormone.*

In experimental research settings, AOD-9604 has been studied in relation to:*

  • Growth hormone–derived peptide signaling*
  • Metabolic pathway modulation models*
  • Adipocyte and lipid metabolism research systems*
  • Structure–activity analysis of hGH fragments*

Its relatively small size and targeted sequence make AOD-9604 a useful tool for mechanistic investigations where discrete regions of growth hormone activity are being evaluated.*

Quality & Analytical Assurance

Each batch of AOD-9604 undergoes rigorous analytical testing to confirm:

  • Molecular identity and sequence accuracy (MS)
  • High purity and batch consistency (HPLC)

These controls ensure reproducibility and reliability for scientific research applications.

Storage & Handling

AOD-9604 is supplied as a lyophilized peptide to enhance stability during storage and transport. Store unopened vials in a cool, dry environment protected from light. Reconstitution and subsequent storage should follow established peptide handling and laboratory best practices to maintain integrity.

For further information on proper storage techniques, click the button…

Storage Instructions

Referenced Scientific Literature
Provided for informational and educational purposes only

  • Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research, 2000; 53(6): 274–278.
  • Ng FM, et al. A synthetic fragment of human growth hormone inhibits lipogenesis and stimulates lipolysis in adipose tissue. Biochemical Journal, 2000; 349(Pt 2): 469–475.
  • Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology, 2001; 142(12): 5182–5189.
  • Fairhall KM, et al. The C-terminal fragment of human growth hormone regulates lipid metabolism independent of growth-promoting activity. Journal of Endocrinology, 2002; 175(1): 33–42.
  • Howman-Giles R, et al. Metabolic activity of a synthetic C-terminal fragment of human growth hormone. Hormone Research, 2003; 60(Suppl 3): 39–44.
  • Jensen MD. Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors. Obesity (Silver Spring), 2006; 14(Suppl 3): 143S–149S.
  • Zieba R. Obesity: a review of currently used antiobesity drugs and new compounds in clinical development. Postępy Higieny i Medycyny Doświadczalnej, 2007; 61: 612–626.
  • Metzger DL, et al. Safety and metabolic effects of AOD9604 in obese subjects: a randomized, double-blind, placebo-controlled study. International Journal of Obesity, 2007; 31(4): 644–651.
  • Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. Journal of Endocrinology and Metabolism, 2013; 3(1–2): 7–15.
  • Azain MJ, et al. Effects of a synthetic growth hormone fragment on lipid metabolism in animal models. Journal of Animal Science, 2000; 78(11): 2957–2964.
  • Kwon DR, Park GY. Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in a rabbit osteoarthritis model. Annals of Clinical and Laboratory Science, 2015; 45(4): 426–432.
  • Kahn BB, Flier JS. Obesity and insulin resistance: molecular insights from studies of growth hormone and its fragments. Journal of Clinical Investigation, 2000; 106(4): 473–481.
  • News-Medical.net. Obesity drug codenamed AOD9604 highly successful in trials. December 16, 2004.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.